nasdaq:cara
|
67344
|
Mar 24th, 2024 12:00AM
|
Cara Therapeutics
|
5.7K
|
85.00
|
Open
|
|
Mar 24th, 2024 12:03AM
|
Mar 24th, 2024 12:03AM
|
Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica.
|
Open
|
|
Open
|
4 Stamford Plaza
|
Stamford
|
Connecticut
|
US
|
06902
|
|
Cara Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:cara
|
67344
|
Mar 23rd, 2024 12:00AM
|
Cara Therapeutics
|
5.7K
|
85.00
|
Open
|
|
Mar 22nd, 2024 11:10PM
|
Mar 23rd, 2024 06:29PM
|
Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica.
|
Open
|
|
Open
|
4 Stamford Plaza
|
Stamford
|
Connecticut
|
US
|
06902
|
|
Cara Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:cara
|
67344
|
Mar 22nd, 2024 12:00AM
|
Cara Therapeutics
|
5.7K
|
85.00
|
Open
|
|
Mar 21st, 2024 11:10PM
|
Mar 22nd, 2024 06:18PM
|
Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica.
|
Open
|
|
Open
|
4 Stamford Plaza
|
Stamford
|
Connecticut
|
US
|
06902
|
|
Cara Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:cara
|
67344
|
Mar 21st, 2024 12:00AM
|
Cara Therapeutics
|
5.7K
|
85.00
|
Open
|
|
Mar 20th, 2024 11:16PM
|
Mar 21st, 2024 05:01PM
|
Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica.
|
Open
|
|
Open
|
4 Stamford Plaza
|
Stamford
|
Connecticut
|
US
|
06902
|
|
Cara Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:cara
|
67344
|
Mar 20th, 2024 12:00AM
|
Cara Therapeutics
|
5.7K
|
85.00
|
Open
|
|
Mar 19th, 2024 11:31PM
|
Mar 20th, 2024 07:01PM
|
Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica.
|
Open
|
|
Open
|
4 Stamford Plaza
|
Stamford
|
Connecticut
|
US
|
06902
|
|
Cara Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:cara
|
67344
|
Mar 19th, 2024 12:00AM
|
Cara Therapeutics
|
5.7K
|
85.00
|
Open
|
|
Mar 18th, 2024 10:57PM
|
Mar 19th, 2024 05:34PM
|
Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica.
|
Open
|
|
Open
|
4 Stamford Plaza
|
Stamford
|
Connecticut
|
US
|
06902
|
|
Cara Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:cara
|
67344
|
Mar 18th, 2024 12:00AM
|
Cara Therapeutics
|
5.7K
|
85.00
|
Open
|
|
Mar 17th, 2024 11:19PM
|
Mar 18th, 2024 06:45PM
|
Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica.
|
Open
|
|
Open
|
4 Stamford Plaza
|
Stamford
|
Connecticut
|
US
|
06902
|
|
Cara Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:cara
|
67344
|
Mar 17th, 2024 12:00AM
|
Cara Therapeutics
|
5.7K
|
86.00
|
Open
|
|
Mar 17th, 2024 12:03AM
|
Mar 17th, 2024 12:03AM
|
Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica.
|
Open
|
|
Open
|
4 Stamford Plaza
|
Stamford
|
Connecticut
|
US
|
06902
|
|
Cara Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:cara
|
67344
|
Mar 16th, 2024 12:00AM
|
Cara Therapeutics
|
5.7K
|
87.00
|
Open
|
|
Mar 15th, 2024 10:46PM
|
Mar 16th, 2024 06:33PM
|
Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica.
|
Open
|
|
Open
|
4 Stamford Plaza
|
Stamford
|
Connecticut
|
US
|
06902
|
|
Cara Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:cara
|
67344
|
Mar 15th, 2024 12:00AM
|
Cara Therapeutics
|
5.7K
|
87.00
|
Open
|
|
Mar 14th, 2024 11:48PM
|
Mar 15th, 2024 08:20AM
|
Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica.
|
Open
|
|
Open
|
4 Stamford Plaza
|
Stamford
|
Connecticut
|
US
|
06902
|
|
Cara Therapeutics
|
Health Care
|
Pharmaceuticals & Biotechnology
|